Original Research J Clin Psychiatry August 2026

Pharmacokinetics of Viloxazine ER (Viloxazine Extended-Release Capsules) in Breast Milk of Healthy Lactating Women

JCP 2026;87(3):10.4088/JCP.25m16169

Full Article Read the complete peer-reviewed article in J Clin Psychiatry. JCP 2026;87(3):10.4088/JCP.25m16169 Clinical Summary Postpartum women with attention-deficit/hyperactivity disorder increasingly need treatment decisions that account for breastfeeding, but lactation data for ADHD medications remain sparse. This study addresses a practical question clinicians face: how much viloxazine extended-release reaches breast milk at the maximum recommended adult dose, and what infant exposure that translates to. FAQ How much viloxazine extended-release gets into breast milk? 9 questions
Key Takeaways In this inpatient phase 4 study, lactating women received the maximum recommended adult dose of viloxazine ER, 600 mg/d, for 3 consecutive days, which helps clinicians interpret the low milk transfer findings under a higher-exposure dosing scenario rather than a subtherapeutic one. 6 takeaways Clinical Guide How should clinicians counsel a breastfeeding patient with ADHD who is taking or considering viloxazine extended-release? 7 steps
Physicians Postgraduate Press, Inc. (PPP) makes no warranties about the accuracy or completeness of any information published in The Journal of Clinical Psychiatry or other PPP materials, and disclaims liability for any use or non-use of that information. Clinicians should not rely solely on these materials and should exercise their own professional judgment when making patient care decisions on an individualized basis.

Learn More About Psychedelics in Psychiatry

Explore the Collection
Neural network illustration symbolizing psychedelic research advancements

Subscribe to read
more articles

Subscribe